Malignant Mesothelioma Drug Submission

ONCONASE is being discussed for the treatment of malignant mesothelioma; a pre-NDA meeting is planned in January 2009 to discuss the final components. The actual effectiveness may still be statistically indeterminate, and conditional on a very specific data set regarding patients who failed one prior chemotherapy regimen. The U.S. commercial rights for ONCONASE are leased to to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. from Alfacell Corporation.